Safety and usage of darbepoetin alfa in children with chronic kidney disease: prospective registry study
2016
Abstract
Background Limited prospective data are available on the long-term safety of darbepoetin alfa (DA) for treating anemia in children with chronic kidney disease (CKD). Methods In this prospective, phase IV, observational registry study, children = 1 transfusion.
Conclusions No new safety signals for DA were identified in children receiving DA for CKD anemia for <= 2 years. Based on Hb concentrations and transfusion requirements, DA was effective at managing anemia in these patients.